North America Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 REGULATIONS: NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
6.1.5 GROWING MEDICAL TOURISM
6.2 RESTRAINTS
6.2.1 LACK OF STRONG CLINICAL EVIDENCE
6.2.2 HIGH COST
6.2.3 LACK OF REIMBURSEMENT
6.3 OPPORTUNITIES
6.3.1 TECHNOLOGICAL ADVANCEMENTS
6.3.2 EMERGENCE OF NEW PLAYERS
6.3.3 UNTAPPED MARKET
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATION
6.4.2 SHORTAGE OF SKILLED PERSONNEL
7 COVID-19 IMPACT ON NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
7.5 CONCLUSION:
8 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
8.1 OVERVIEW
8.2 WHOLE GENOME SEQUENCING
8.3 ARRAY-BASED TESTS
9 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
9.1 OVERVIEW
9.2 CYP2C19
9.3 CYP2C9 AND VKORC1
9.4 CYP2D6
9.5 HLA-B
9.6 HTR2A/C
9.7 HLA-A
9.8 CYP3A4
9.9 SLC6A4
9.10 MTHFR
9.11 COMT
9.12 OTHERS
10 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 PRESCRIPTION DRUGS
10.3 OVER-THE-COUNTER MEDICATIONS
10.4 RECREATIONAL DRUGS
10.5 VITAMINS/NUTRACEUTICALS
11 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
11.1 OVERVIEW
11.2 SALIVA
11.3 BLOOD
12 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DRUG DEVELOPMENT
12.3 CLINICAL PRACTICE
13 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
13.1 OVERVIEW
13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.3 HEALTHCARE PROVIDERS
13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
13.5 OTHERS
14 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 RETAIL PHARMACIES
14.3 HOSPITAL PHARMACIES
14.4 MAIL-ORDER PHARMACIES
14.5 DIRECT-TO-CUSTOMER SERVICES
15 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 MYRIAD GENETICS, INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 THERMO FISHER SCIENTIFIC INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 STADA ARZNEIMITTEL AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SONIC HEALTHCARE
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 ILLUMINA, INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 AB-BIOTICS, S.A.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ALTHEADX
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 BIOGENIQ INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 COLOR
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.10 CNSDOSE
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 CORIELL LIFE SCIENCES
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 DYNAMIC DNA LABORATORIES
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 GENELEX
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 GENOMIND, INC.
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 GENXYS
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 HEALTHSPEK
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 LUMINEX CORPORATION
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 MILLENNIUM HEALTH
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENTS
18.20 MYDNA LIFE AUSTRALIA PTY LTD.
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENT
18.21 ONEOME
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 OMECARE
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.23 PERKINELMER INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 REVENUE ANALYSIS
18.23.3 PRODUCT PORTFOLIO
18.23.4 RECENT DEVELOPMENTS
18.24 R-BIOPHARM AG
18.24.1 COMPANY SNAPSHOT
18.24.2 PRODUCT PORTFOLIO
18.24.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS